Former Intuitive Surgical Executive Joins Capstan Medical Board as Company Advances Robotic Structural Heart Platform

Source: MedRobot

Reprint Requirements: You can directly repost, but please credit the source at the beginning of the article.

# Professional Experience: Deeply Involved in the Scaling Process of the Robotic Platform

Marshall Mohr is a senior executive in the medical technology and robotics fields, with nearly two decades of experience in executive and board-level roles.

He joined Intuitive Surgical in 2006, initially serving asSenior Vice President and Chief Financial Officer (SVP & CFO)During the company's rapid growth phase, he led and supported the establishment of its financial and operational systems. Subsequently, Mohr was promoted to Executive Vice President in 2018 and appointed as the Executive Vice President of Global Business Services in 2022, responsible for the scaled expansion of the company’s global infrastructure, processes, systems, and business models.

During his tenure at Intuitive Surgical, Mohr witnessed and participated in the continuous global expansion of the da Vinci surgical robot platform. His experience also made him one of the few managers in the medical robotics industry to have long-term involvement in platform operations and governance. He left Intuitive Surgical in 2024.

In addition to Capstan Medical, Mohr currently serves asVeeva Systems、Pacific Biosciences of CaliforniaAndSRI InternationalThe board members remain actively involved in fields related to life sciences, medical technology, and scientific research innovation.

In Capstan Medical's statement, Mohr noted that the technical pathway the company is exploring could offer new treatment options for patients with high-risk heart valve diseases and may reduce the overall burden on both patients and doctors at clinical and operational levels.

# Company Introduction: Focusing on the Robotic Approach to Structural Heart Disease

Capstan Medical, founded in 2020 and headquartered in Santa Cruz, California, is a medical robotics startup focused on minimally invasive treatments for structural heart disease. The company's core direction is toRobotics, Transcatheter Interventions, and Novel Cardiac Valve ImplantsCombined, it is used to treat complex cardiac valve diseases represented by mitral and tricuspid valve conditions.

Currently, Capstan Medical is developing a set of robotically-enabled transcatheter solutions aimed at overcoming the limitations of existing treatment methods in terms of patient suitability, procedural precision, and stability.
In March 2025, the company completed the first batch of human mitral valve replacement surgeries, marking the first time its robotic structural heart disease platform entered real-world clinical application. The company previously stated that it hopes to submit a Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) around 2028, based on subsequent clinical progress.

At the capital level, Capstan Medical completed a $110 million Series C financing round by the end of 2024, providing financial support for its clinical research, system enhancement, and long-term development.

# Conclusion

From the public information, Marshall Mohr's joining Capstan Medical's board of directors is an adjustment to the company’s governance structure and long-term capability allocation during a critical phase of development.
In the complex field where structural heart disease meets medical robotics, clinical validation, regulatory pathways, and scalability often constrain each other. How to reserve space for future expansion while technology is gradually being implemented has become a critical issue that companies need to address at this stage.